Receipt of GMP Grade Monepantel Tablets for Phase II Dog Cancer Trials

- GMP monepantel tablets arrive from US to subsidiary Epichem Pty Ltd
- Stability studies for shelf-life support commencement of trial
- Shipment of tablets to veterinarians scheduled to commence next week
- Anti-cancer testing to commence in dogs with B cell lymphoma

26 August 2019 – Perth, Australia: PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, is pleased to announce the receipt of 7,750 of its newly developed GMP grade monepantel tablets. The tablets have been logged into Epichem's inventory receipt systems ready for shipment to veterinarians conducting the phase II trial as required. Delivery to the veterinarians is expected to commence this week.

Shipment of the GMP monepantel tablets has occurred following rigorous tests demonstrating that all tablets produced in the scaled manufacturing run are consistent in their size, shape and content. Furthermore, the tablets have been on accelerated stability studies and shown to pass shelf-life requirements supporting that their performance will not be compromised under handling conditions expected following distribution to veterinarians and then to pet owners.

PharmAust's Chief Scientific Officer Dr Richard Mollard commented, "PharmAust is pleased to accept delivery of the newly developed tablets on schedule at its Epichem facility. Furthermore, PharmAust is looking forward to providing these tablets to veterinarians and commencing the Phase II study, testing anti-cancer efficacy in pet dogs with B cell lymphoma."

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com

About PharmAust (PAA):
PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated Aus$3.0m in revenues in the 2018 FY.